__NUXT_JSONP__("/drugs/Gilteritinib", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:"gilteritinib fumarate",conditionIndication:"Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.",inn:"gilteritinib",marketingAuthorisationDate:"2019-10-24 00:00:00",marketingAuthorisationHolder:"Astellas Pharma Europe B.V.",medicineName:"Xospata",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fxospata"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1254053-43-4",chebiId:b,chemicalFormula:b,definition:"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.",fdaUniiCode:"66D92MGC8M",identifier:"C116722",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C129825","C1967"],synonyms:["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide","ASP-2215","ASP2215","GILTERITINIB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FGilteritinib",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Gilteritinib","","2021-10-30T13:19:12.973Z")));